title: Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.
abstract: OBJECTIVE
  A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment. Further research of PGB vs. non-pregabalin (non-PGB) treatment was carried out to assess if the use of more specific NP-targeting drugs, such as PGB, in combined therapy, in patients with cancer-related NP, provides better health outcomes.
  
  
  METHODS
  Post hoc analysis of PGB- vs. non- PGB-treated patients in a 2-month epidemiological, prospective, multicentre study to assess NP prevalence and management in cancer pain patients visiting radiotherapy oncologic units. Patients undertook the Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), the Medical Outcomes Sleep Scale (MOS-Sleep) and the short form (SF-12) Health Survey.
  
  
  RESULTS
  A total of 273 patients with no previous PGB treatment: 162 were treated with PGB polytherapy and 111 with other treatments. At 8 weeks, satisfaction with treatment was 92.6% (PGB) vs. 78.9% (non-PGB), p=0.0024, and benzodiazepine use 37.8% (non-PGB) vs. 19.8% (PGB), p=0.0009. The decreases in BPI total pain intensity and total interference with activities and in MOS overall sleep problems index were significantly larger in the PGB group.
  
  
  CONCLUSIONS
  The addition of more specific NP-targeting drugs to usual treatment, such as PGB, in NP cancer patients provides more satisfaction with treatment and better outcomes in terms of pain intensity, interference with activities and sleep than treatments without specific NP-targeting drugs. Anxiolytic profile of PGB could allow for less use of benzodiazepines.
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario La Paz, Madrid, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Mańas
authors.forename: Juan Pablo
authors.initials: JP
authors.lastname: Ciria
authors.forename: María Carmen
authors.initials: MC
authors.lastname: Fernández
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Gonzálvez
authors.forename: Virginia
authors.initials: V
authors.lastname: Morillo
authors.forename: María
authors.initials: M
authors.lastname: Pérez
authors.forename: Xavier
authors.initials: X
authors.lastname: Masramon
authors.forename: Vanessa
authors.initials: V
authors.lastname: López-Gómez
mesh_terms: D000368:Aged; D000698:Analgesia / Q000379:methods; D000700:Analgesics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D000069583:Pregabalin; D012189:Retrospective Studies; D012890:Sleep / Q000187:drug effects* / Q000502:physiology; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid